Risk of Herpes Zoster in Adults Under 50 Without Chickenpox History

Understanding the True Risk

The majority of adults (88-91%) have been exposed to varicella zoster virus (VZV) even without recalled chickenpox, making them capable of developing shingles, according to the Centers for Disease Control and Prevention 1
Seroprevalence studies demonstrate that 88-91% of adults have VZV antibodies even when they don't recall having chickenpox, indicating subclinical or forgotten childhood infection, as reported by the American Academy of Pediatrics 1
Varicella seropositivity reached 88% in adults aged 21-30 years in the pre-vaccine era, meaning the vast majority without recalled chickenpox history were actually VZV-exposed, according to the World Health Organization 1

Truly VZV-seronegative individuals (the minority without chickenpox history) have essentially zero risk of herpes zoster because you cannot reactivate a virus you've never been infected with, as stated by the Infectious Diseases Society of America 2
VZV-seropositive individuals without recalled chickenpox (the majority) have the same herpes zoster risk as anyone else with prior VZV exposure, with baseline incidence of 4.97 cases per 1000 person-years in the general adult population, according to the National Institutes of Health 3
Risk increases with age, immunosuppression, and comorbidities (diabetes, rheumatoid arthritis, SLE, cancer, HIV), as reported by the American College of Rheumatology 4, 2

No routine herpes zoster vaccination is recommended for immunocompetent adults under 50 without chickenpox history, as standard zoster vaccines (both ZVL and RZV) are approved for ages 50 and older, according to the Centers for Disease Control and Prevention 2, 3
Consider varicella vaccination if confirmed VZV-seronegative by serology, using 2 doses separated by 4 weeks, as recommended by the American Academy of Family Physicians 1, 5
RZV can be administered to adults aged 18 and older who are or will be immunocompromised, regardless of chickenpox history, according to the Infectious Diseases Society of America 2, 6

Don't assume absence of recalled chickenpox means VZV-seronegative status - most adults have been exposed even without clinical disease, as warned by the American Medical Association 7
Don't unnecessarily delay appropriate vaccination to conduct varicella serology in immunocompetent adults aged 50 and older, as advised by the National Institutes of Health 7
Don't administer live zoster vaccine (ZVL) to immunocompromised patients, even if VZV-seronegative - use RZV instead or consider varicella vaccine, as recommended by the Infectious Diseases Society of America 6, 8

The American College of Immunology recommends that all adults aged 50 years and older receive Shingrix, a recombinant zoster vaccine, regardless of varicella antibody status or history of chickenpox, with a strong recommendation and moderate quality evidence 9
The vaccine efficacy is greater than 90% across all age groups 50 and older, with protection sustained for at least 8-10 years 9

The Centers for Disease Control and Prevention recommends that adults aged 18 years and older who are or will be immunosuppressed, including those on biologics, JAK inhibitors, or other immunomodulators, should receive Shingrix 10, 11
The European League Against Rheumatism recommends that Shingrix is safe for immunocompromised patients because it contains only a recombinant protein, not live virus, and the live zoster vaccine (Zostavax) is contraindicated in this population 10, 11, 12

The Shingrix vaccine causes more injection-site reactions and systemic symptoms compared to placebo, but these are transient and mild-to-moderate, with 9.5% grade 3 injection-site reactions and 11.4% systemic symptoms 9
No serious safety concerns or increased mortality have been identified in large trials, and in autoimmune disease patients, mild disease flares can occur but without serious adverse events 9, 12

If VZV IgG antibody testing confirms an individual is seronegative, they should receive the varicella vaccine instead of or before the shingles vaccine, which requires 2 doses of single-antigen varicella vaccine at least 4 weeks apart, as recommended by the Annals of Internal Medicine 13
The varicella vaccine is indicated for seronegative individuals, with a 2-dose series, as supported by the Journal of Crohn's and Colitis 14

The Centers for Disease Control and Prevention (CDC) and other guideline societies recommend that immunocompromised adults aged 18-49 years receive Shingrix, regardless of chickenpox history, as it is safe and contains only a recombinant protein, not live virus, as stated in Gut 15
For immunocompromised adults, a shorter schedule with the second dose given 1-2 months after the first dose may be considered, according to the Gut journal 15